Translating world leading research in NMT into a pipeline of first-in-class ADC medicines for cancer

Myricx Bio (“Myricx”) is a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer. NMT is an enzyme that adds a specific lipid modification to a number of protein targets key to cancer cell survival.

We are advancing a pipeline of ADCs based on our novel NMT inhibitor (NMTi) payload chemistry platform to address serious unmet needs in oncology. Our proprietary ADCs have demonstrated compelling preclinical efficacy and safety across multiple solid tumour associated antigens and specific cancer cell types.

Investors

A private company, Myricx is backed by a strong syndicate of experienced life science and healthcare investors including Abingworth, Brandon Capital, British Business Bank, Cancer Research Horizons, Eli Lilly and Company, Novo Holdings, and Sofinnova Partners.

Learn more

Location

Myricx is located within state-of the art office and laboratory facilities at the London Innovation Centre and benefits from the wider Canary Wharf life sciences ecosystem and excellent biotech network.

X